Who Is Nicholas Kadysh? Chief Executive Officer of PharmAla Biotech
Founding Chief Executive Officer of PharmAla Biotech.
Nicholas Kadysh serves as the Chief Executive Officer of PharmAla Biotech.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
As the founding Chief Executive Officer of PharmAla Biotech, Kadysh leads the company's GMP-grade MDMA supply arrangements across international markets, including active programs in the United States and partnerships in New Zealand and Australia.
Where Nicholas Kadysh Is Now
- Current role: Chief Executive Officer markets.businessinsider.com
- Organization: PharmAla Biotech markets.businessinsider.com
- Known for: Founding Chief Executive Officer of PharmAla Biotech markets.financialcontent.com
- Recent news: Announcing MDMA supply arrangements in New Zealand and active supply into U.S. VA and DHA programs markets.businessinsider.com
Nicholas Kadysh currently serves as the Chief Executive Officer of PharmAla Biotech markets.businessinsider.com.
International Supply and Commercial Partnerships
Kadysh stated that Medsafe's decision provides psychiatrists in New Zealand a pathway to treat PTSD using MDMA markets.businessinsider.com.
Regarding the partnership in New Zealand, Kadysh stated that Rua Bioscience possessed the licences, quality systems, and prescriber relationships to deliver GMP-grade MDMA from day one markets.businessinsider.com.
In Australia, Kadysh stated that Cortexa provides PharmAla with a dedicated sales organization and local expertise in commercial MDMA-assisted therapies nasdaq.com.
United States Supply Operations
Kadysh stated that PharmAla has GMP MDMA in the United States and active supply into U.S. VA and DHA programs markets.financialcontent.com.
Corporate Transactions and Strategic Planning
Kadysh stated that PharmAla executed an excellent quarter of sales and completed its transaction with Jupiter Neuroscience markets.businessinsider.com.
Kadysh stated that engaging Canaccord Genuity as a banking partner was the logical next step following PharmAla's transaction with Jupiter Neurosciences markets.financialcontent.com.
He stated that having a single exclusive partner across financing and strategic alternatives allows PharmAla to evaluate its options in a disciplined way markets.financialcontent.com.
Frequently asked questions
Who is Nicholas Kadysh?
Nicholas Kadysh is the founding Chief Executive Officer of PharmAla Biotech markets.financialcontent.com.
What is Nicholas Kadysh's current role?
Nicholas Kadysh serves as the Chief Executive Officer of PharmAla Biotech markets.businessinsider.com.
What did Nicholas Kadysh state about Medsafe's decision in New Zealand?
Kadysh stated that Medsafe's decision gives New Zealand psychiatrists a path to treat PTSD with MDMA markets.businessinsider.com.
What has Nicholas Kadysh said about Rua Bioscience?
Kadysh stated that Rua Bioscience possessed the licences, quality systems, and prescriber relationships to deliver GMP-grade MDMA from day one markets.businessinsider.com.
Does PharmAla have MDMA supply in the United States according to Nicholas Kadysh?
Yes, Kadysh stated that PharmAla has GMP MDMA in the United States and active supply into U.S. VA and DHA programs markets.financialcontent.com.
What role does Cortexa play according to Nicholas Kadysh?
Kadysh stated that Cortexa provides PharmAla with a dedicated sales organization and local expertise in commercial MDMA-assisted therapies nasdaq.com.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Nicholas Kadysh or PharmAla Biotech. See more people in psychedelic medicine.